Shanghai Pharmaceuticals (SHA:601607, HKG:2607) recorded a 6.4% rise in attributable profit in the first quarter of 2026 to 1.42 billion yuan from 1.33 billion yuan a year prior, according to a Wednesday Hong Kong bourse filing.
The pharma company's earnings per share rose to 0.3823 yuan from 0.3595 yuan in the corresponding period of the previous fiscal year.
Revenue jumped 6.4% to 75.3 billion yuan from 70.8 billion yuan in the year-ago period.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments